Background
==========

TAFRO syndrome is a unique clinicopathologic variant of multicentric Castleman's disease that has recently been identified in Japan \[[@B1]\]. The syndrome is characterized by a constellation of symptoms: Thrombocytopenia, Anasarca, reticulin Fibrosis of the bone marrow, Renal dysfunction and Organomegaly (TAFRO). Although elevated levels of interleukin-6 (IL-6) and vascular endothelial cell growth factor (VEGF) are seen in the serum and effusions of patients with TAFRO syndrome, the pathogenesis of the disease remains obscure \[[@B1]\]. Previous reports \[[@B2]-[@B6]\] have shown that patients respond to immunosuppressive therapy, but the disease has resulted in a fatal outcome in some patients \[[@B5],[@B6]\]. This disease occurs in the middle-aged and elderly \[[@B1]\]; no case of TAFRO syndrome in adolescence has been reported to date.

Here we report the case of a 15-year-old Japanese boy with TAFRO syndrome successfully treated with anti-IL-6 receptor antibody (tocilizumab, TCZ) and monitored with serial precise cytokine profiles. This is the first report of this disease in an adolescent.

Case presentation
=================

Clinical course
---------------

A 15-year-old Japanese boy was referred to us with fever of unknown origin of 2 weeks' duration. He had a systolic murmur and hepatosplenomegaly. The patient's superficial lymph nodes were swollen, with a maximum diameter of 3.0 cm. Laboratory tests showed elevations in C-reactive protein (CRP; 17.8 mg/dL), soluble IL-2 receptor (2,467 IU/mL), lactate dehydrogenase (511 IU/L) and D-D dimer (5.6 μg/mL). The patient had decreased total protein (5.1 g/dL), albumin (1.8 g/dL), immunoglobulin G (729 mg/dL) and cholinesterase (48 IU/L). Complete blood cell count and serum levels of liver enzymes, blood urea nitrogen and creatinine (Cr) were within normal range. Urinalysis showed mild proteinuria of 0.4 mg/mg ∙ Cr without hematuria. Enhanced whole body computed tomography demonstrated systemic lymphadenopathy, hepatosplenomegaly, renal enlargement and anasarca (Figure [1](#F1){ref-type="fig"}A--C).Bone marrow biopsy revealed a hyperplastic marrow with megakaryocytic hyperplasia (Figure [2](#F2){ref-type="fig"}A) and mild reticulin fibrosis (Figure [2](#F2){ref-type="fig"}B). An 18-fluoro-deoxyglucose (FDG) positron emission tomography scan showed weak FDG uptake by the bilateral cervical and inguinal lymph nodes and spleen. Biopsies of the lymph nodes showed scattered lymphoid follicles with atrophic germinal centers and enlarged follicular dendritic cells, with surrounding concentric rings of small lymphocytes and penetrating vessels (lollipop-like appearance; Figure [2](#F2){ref-type="fig"}C). The interfollicular area was characterized by prominent vascularity and moderate numbers of mature plasma cells (Figure [2](#F2){ref-type="fig"}D). Immunological studies showed decreased numbers of B-cells and CD57+ T-cells in the germinal centers. Immunostaining for CD21 demonstrated tight/concentric and expanded/disrupted patterns of follicular dendritic cells (Figure [2](#F2){ref-type="fig"}E). These findings were compatible with the mixed type of Castleman's disease.

![**Imaging study.** The patient had pleural effusion **(A)** and severe hepatosplenomegaly **(B)**. Multiple lymph node enlargements were observed in the mesentery and in the paraaortic lymph nodes at admission (arrows in white) **(C)**. After two weekly TCZ infusions, systemic lymphadenopathy, hepatosplenomegaly and renal enlargement improved. However, pleural fluid, ascites and subcutaneous edema worsened **(D--F)**.](1471-2431-14-139-1){#F1}

![**Histopathological findings of the bone marrow (A, B) and lymph nodes (C--E). (A)** Hematoxylin and Eosin stain × 200. Bone marrow biopsy showed hypercellular marrow with increased numbers of megakaryocytes, including micro- and multi-separated nuclear megakaryocytes and megaloblastic change. **(B)** Silver stain × 200. Silver stain showed mild reticulin fibrosis. **(C)** Hematoxylin and Eosin stain × 200. A high-power field in the lymph node showed scattered lymphoid follicles with atrophic germinal centers, enlarged follicular dendritic cells, surrounding concentric rings of small lymphocytes, and penetrating vessels. **(D)** Hematoxylin and Eosin stain × 200. The interfollicular area was characterized by the proliferation of highly dense endothelial vessels and moderate numbers of mature plasma cells. **(E)** CD21 immunostain × 200. Immunostaining for CD21 showed tight/concentric and expanded/disrupted pattern of follicular dendritic cells. These findings were compatible with mixed-type Castleman's disease.](1471-2431-14-139-2){#F2}

Autoantibodies, serum M-protein and urine Bence-Jones protein were not detected in this patient. Blood culture and quantitative PCR examinations for cytomegalovirus, Epstein-Barr virus, human herpes virus type 8 (HHV-8) and human immunodeficiency virus (HIV) were all negative. There were no significant pathological findings of malignancy in lymph node or liver biopsies.Despite treatment with antibiotics and albumin, the disease progressed markedly to respiratory distress, oliguric renal failure, anemia and thrombocytopenia. Methylprednisolone pulse therapy at a dose of 1000 mg/day for 3 consecutive days was initiated on day 10 after admission, but the patient's fever persisted and his CRP remained elevated. The patient was diagnosed with multicentric Castleman's disease and treatment was initiated with weekly TCZ at a dose of 8 mg/kg, high dose intravenous immunoglobulin and 80 mg of prednisolone (PSL) daily. Weekly TCZ dramatically improved the patient's symptoms and laboratory findings. However, anasarca persisted (Figure [1](#F1){ref-type="fig"}D--F). With removal of ascites, anasarca gradually disappeared.

One month after the initiation of TCZ therapy, the patient was forced to decrease his PSL dose because of steroid psychosis. In addition, he developed blisters over his entire body and was forced to discontinue treatment with TCZ because drug reaction or viral infection was suspected. Paraneoplastic pemphigus and pemphigoid, which are reported complications of Castleman's disease \[[@B7]-[@B9]\], were ruled out by negative antibody and immunofluorescence testing. We diagnosed the patient's skin lesions as toxic epidermal necrolysis by pathology, but were unable to determine the cause.After treatment for multicentric Castleman's disease was discontinued, the patient's clinical symptoms reappeared with elevated cytokine levels. Restarting weekly TCZ resulted in improvement in these findings (Figure [3](#F3){ref-type="fig"}). During this treatment, the patient's skin lesions also resolved. After cytokine levels normalized 4 months after admission, the patient was discharged. One year after disease onset, the patient continued treatment with 5 mg PSL daily and TCZ every 3 weeks without any signs of recurrence. His clinical symptoms completely matched those of TAFRO syndrome.

![**Patient's clinical course. A**: Cytokine profiles; **B**: Clinical symptoms and complications; **C**: Treatment; **D**: Laboratory data. IL-6: interleukin-6; IVIG: intravenous injection of immunoglobulin (⇩); mPSL: methylprednisolone; PSL: prednisolone; sTNF-R: soluble tumor necrosis factor receptor; TCZ: tocilizumab (↓); TEN: toxic epidermal necrolysis; VEGF: vascular endothelial cell growth factor.](1471-2431-14-139-3){#F3}

Cytokine profile of serum, plasma and ascites
---------------------------------------------

In the acute phase of the disease, the patient's serum cytokine levels of IL-6, IL-7, IL-10, IL-12p70, IL-15, IL-16, soluble tumor necrosis factor receptors I and II (sTNF-R I/II), VEGF, neopterin, interferon gamma-induced protein 10 (IP-10), macrophage inflammatory protein 1β (MIP-1β), eotaxin-3 and monocyte chemoattractant protein 1 (MCP-1) were elevated (Table [1](#T1){ref-type="table"}). After initiation of TCZ therapy, serum IL-6 levels increased because of IL-6 receptor blocking by TCZ (Figure [3](#F3){ref-type="fig"}). After repeated TCZ infusions, most of the serum and plasma cytokine/chemokine levels decreased, including IL-6. When TCZ therapy was discontinued because of steroid psychosis and toxic epidermal necrolysis, cytokine levels transiently increased. After restarting TCZ therapy, cytokine levels decreased once more (Figure [3](#F3){ref-type="fig"}).

###### 

Cytokine profiles of serum, plasma and ascites

                             **Serum**   **Ascites**   **Reference range**                    
  ---------------- -------- ----------- ------------- --------------------- -------- -------- ------------
  IL-1α            pg/mL      \<1.37       \<1.37            \<1.37          \<1.37   \<1.37   0.29--62.1
  IL-1β            pg/mL      \<0.640      \<0.640           \<0.640         1.620    0.826    0.11--24.3
  IL-2             pg/mL      \<1.78       \<1.78            \<1.78           6.84     2.00    0.22--2.68
  IL-4             pg/mL       0.542        0.376             0.642           2.90     3.84       N.A.
  IL-5             pg/mL       \<3.2        \<3.2             \<3.2           6.70     5.72    0.11--0.62
  IL-6             pg/mL        29           5.0               5.0            4400     4700       \<3
  IL-7             pg/mL        146         54.6              89.0            17.6     20.8    0.37--2.78
  IL-8             pg/mL        230          348              34.8           \>798     522     1.48--1720
  IL-10            pg/mL       3.28         23.2              1.36            8.00     10.4    0.06--3.08
  IL-12p70         pg/mL       3.40         3.16              3.20            5.30     31.0    0.26--0.38
  IL-12/IL-23p40   pg/mL        488         49.2               330            45.2     93.6    13.1--159
  IL-13            pg/mL       6.98         8.28              8.90            17.0     12.0    0.60--2.78
  IL-15            pg/mL       11.6         36.8              4.74            34.8     43.6    0.56--3.01
  IL-16            pg/mL       1054         1266               628            366      610      24--137
  IL-17A           pg/mL      \<17.7       \<17.7            \<17.7          \<17.7   \<17.7   0.28--4.87
  IL-18            pg/mL        360          230               182            75.0     80.0      \<500
  IFN-γ            pg/mL       14.8        \<5.12             22.2            19.3     10.7    0.64--14.4
  TNF-α            pg/mL        \<5          \<5              N.D.            \<5      \<5        \<5
  sTNF-RI          pg/mL       7300         10200             1230            8000     4800    484--1407
  sTNF-RII         pg/mL       9600         21800             3450            6000     4200    829--2262
  VEGF             pg/mL       N.D.         178\*            16.4\*           1860     1210     \<38.3\*
  Neopterin        nmol/L      10.0         28.5              4.00            16.7     15.5       \<5
  GM-CSF           pg/mL       \<3.8        \<3.8             \<3.8          \<3.8    \<3.8    0.18--0.18
  IP-10            pg/mL      \>2000       \>2000              928            1200     1440    28.5--237
  MIP-1α           pg/mL       87.6         56.0             \<55.2           71.6     77.2     12--202
  MIP-1β           pg/mL        628          480               452            166      188     7.29--95.2
  Eotaxin          pg/mL       76.8        \<48.8              228            85.6     162     19.0--145
  Eotaxin-3        pg/mL       61.2         68.0              76.0            404      624     7.63--8.73
  TARC             pg/mL        132         58.8               860            30.2     33.2    5.39--70.0
  MCP-1            pg/mL      \>1508         528               632           \>1508   \>1508   75.7--205
  MCP-4            pg/mL        180         47.2               209            36.2     39.2    11.2--117
  MDC              pg/mL       1960          330              2740           \<320     374     606--3249

IL: interleukin; IFN: interferon; TNF: tumor necrosis factor; sTNF-RI: soluble tumor necrosis factor receptor type I; sTNF-RII: soluble tumor necrosis factor receptor type II; VEGF: vascular endothelial cell growth factor; GM-CSF: granulocyte macrophage colony-stimulating factor; IP-10: interferon gamma-induced protein 10; MIP: macrophage inflammatory protein; TARC: thymus and activation regulated chemokine; MCP: monocyte chemoattractant protein; MDC: macrophage-derived chemokine; N.A: not available; N.D: not determined: \*: values derived from plasma.

Aspiration of ascites was performed twice with a total volume of 11.2 L removed. IL-6 and VEGF levels in the ascitic fluid were extremely high (Table [1](#T1){ref-type="table"}).

Cytokine and chemokine determination
------------------------------------

Serum and plasma concentrations of IL-6, IL-18, tumor necrosis factor α (TNF-α), sTNF-R I/II, VEGF and neopterin were determined by using the following enzyme-linked immunosorbent assay (ELISA) kits: neopterin (IBL, Hamburg, Germany); IL-6, TNF-α, sTNF-R I/II and VEGF (R&D Systems Inc., Minneapolis, MN, USA); and IL-18 (MBL, Nagoya, Japan). Other cytokines/chemokines were determined by electrochemiluminescence immunoassay (MSD, Rockville, MD, USA).

Discussion
==========

Multicentric Castleman's disease is thought to comprise several disease entities, including idiopathic and secondary multicentric Castleman's disease in conditions such as POEMS syndrome, autoimmune disease-associated lymphadenopathy and malignant lymphoma \[[@B10],[@B11]\]. In contrast to its prevalence in Western countries \[[@B11],[@B12]\], multicentric Castleman's disease associated with HIV and/or HHV-8 is uncommon in Japan, where the disease usually demonstrates a relatively chronic course. Kojima et al. classified Japanese multicentric Castleman's disease into two subtypes on the basis of clinicopathological findings: (1) idiopathic plasmacytic lymphadenopathy with polyclonal hyperimmunoglobulinemia (IPL type) and (2) non-IPL type, which is atypical multicentric Castleman's disease characterized by mixed-type or hyaline vascular-type histology and a high incidence of massive effusion and autoimmune disease \[[@B13]\]. IPL is considered a homogeneous disease entity, whereas non-IPL type is a heterogeneous cluster of disease entities \[[@B13],[@B14]\].

Recently Takai et al. reported three cases that shared a constellation of clinical symptoms: thrombocytopenia, anasarca, fever, reticulin fibrosis of the bone marrow and organomegaly. These symptoms were tentatively given the clinical name "TAFRO syndrome" to describe the new disease concept \[[@B6]\]. In 2013, Japanese national meetings were held to define TAFRO syndrome more clearly as a systemic inflammatory disease characterized by a constellation of symptoms: thrombocytopenia, anasarca, reticulin fibrosis of the bone marrow, renal dysfunction and organomegaly \[[@B1]\]. Other clinical findings include anemia, immunologic disorder and rarely polyclonal hyper-γ-globulinemia \[[@B1]\]. As a subtype of non-IPL, TAFRO syndrome is characterized histologically as mostly a mixed type of Castleman's disease, with an abnormal follicular dendritic cell network \[[@B1]\]. TAFRO syndrome is considered a novel clinical entity belonging to systemic inflammatory disorders and featuring immunological abnormality beyond the ordinary spectrum of multicentric Castleman's disease \[[@B1]\].

It is thought that the pathogenesis of TAFRO syndrome might be associated with a strong hypercytokine storm, including IL-6 and VEGF \[[@B1],[@B5]\]. In our patient, serum and plasma levels of not only IL-6 and VEGF but also of other cytokines/chemokines were markedly elevated (Table [1](#T1){ref-type="table"}). It is not clear how these cytokines/chemokines are associated with this disease. Further studies are needed to clarify the roles of these cytokines/chemokines. It is interesting that the levels of IL-6 and VEGF in the ascitic fluid of our patient were markedly higher than the levels in his serum and plasma. One previous case has been reported of a patient with severe anasarca and markedly elevated IL-6, suggesting systemic inflammation of the serosa \[[@B3]\].

It is thought that the thrombocytopenia seen in TAFRO syndrome might be caused by an immune-mediated mechanism and can be overcome by anti-inflammatory therapy \[[@B2]-[@B4]\]. The mechanism of renal failure in patients with TAFRO syndrome is not clear because histological examinations of kidneys have not been reported in this disease. Previous studies have reported that patients with Castleman's disease manifest renal symptoms such as nephrotic syndrome and acute renal failure and that histologic findings were heterogeneous, including various glomerular lesions, thrombotic microangiopathy-like lesions, interstitial nephritis and amyloidosis \[[@B15],[@B16]\]. In our case, urinalysis showed mild proteinuria and mildly elevated urinary N-acetyl-beta-D-glucosaminidase and β2-microglobulin without fractural red blood cells in peripheral blood before the onset of renal failure. These findings suggest that the kidney pathophysiology in this case was interstitial nephritis rather than glomerular nephritis, thrombotic microangiopathy or amyloidosis.

Eight cases of TAFRO syndrome have previously been reported \[[@B2]-[@B6]\]. All cases including ours are summarized in Table [2](#T2){ref-type="table"}. This disease generally occurs in the middle-aged and elderly \[[@B1]-[@B6]\]. There are no adolescent cases reported to date, and this is the first case of a young patient with an apparent diagnosis of TAFRO syndrome. All patients were treated with steroids and some improved with the addition of cyclosporine A \[[@B2],[@B6]\] or TCZ \[[@B3],[@B4]\] with rituximab therapy \[[@B3]\]. Unfortunately, three of the eight patients died \[[@B5],[@B6]\], indicating that this syndrome sometimes results in a fatal outcome in spite of treatment.

###### 

Clinical features of TAFRO syndrome in eight previously reported cases and in our case

   **Case no.**   **Age/sex**   **Thrombocytopenia (PLT ×10**^**4**^**/μl)**   **Anasarca**   **Reticulin fibrosis of the bone marrow**   **Renal dysfunction**   **Organomegaly**   **Hb (g/dl)**   **IgG (mg/dl)**   **Serum IL-6 (pg/ml) (normal range)**   **Plasma VEGF (pg/ml) (normal range)**   **Lymph node biopsy**      **Treatment**        **Outcome**      **Ref**
  -------------- ------------- ---------------------------------------------- -------------- ------------------------------------------- ----------------------- ------------------ --------------- ----------------- --------------------------------------- ---------------------------------------- ----------------------- ---------------------- ---------------- -----------
        1            47/F                           1.5                             \+                           \+                              No data                 \+              10.9             1046                        No data                               285 (\<115)                        No data               CHOP, PSL            Survival      \[[@B6]\]
        2            56/M                           1.9                             \+                           \+                                \+                    \+              10.7              863                       7.2 (\<4)                               31 (\<115)                        No data             PSL, IVIG, CyA         Survival     
        3            49/M                           1.0                             \+                           \+                              No data                 \+              11.7             1057                      64.9 (\<4)                              104 (\<115)                     HV-type of CD            PSL, IVIG          Death (MOF)    
        4            49/F                           1.7                             \+                           \+                                \+                    \+               6.2             2611                     11 (No data)                            330 (No data)                       unclear             DEX, PSL, CyA          Survival      \[[@B2]\]
        5            43/F                          \<3.0                            \+                         No data                             \+                    \+              12.6              965                      45.6 (\<4)                              665 (\<115)                     HV-type of CD       mPSL, PSL, RTX, TCZ       Survival      \[[@B3]\]
        6            47/F                           3.9                             \+                           \+                                \+                    \+               9.1             1426                    21.9 (No data)                              No data                       PC-type of CD          PSL, mPSL, TCZ         Survival      \[[@B4]\]
        7            57/F                           1.3                             \+                           \-                                \+                    \+               7.1             1860                    65.5 (No data)                            91 (No data)                       unclear            mPSL, PSL, CHOEP     Death (Sepsis)   \[[@B5]\]
        8            73/M                           2.4                             \+                           \+                                \+                    \+               7.6             7080                     49 (No data)                             25 (No data)                  Mixed type of CD           mPSL, PSL          Death (MOF)    
   Current case      15/M                           3.0                             \+                           \+                                \+                    \+               7.2              729                       29 (\<3)                               178 (\<38.3)                  Mixed type of CD      mPSL, PSL, TCZ, IVIG      Survival           

CD: Castleman's disease; CHOEP: cyclophosphamide, doxorubicin, vincristine, etoposide and prednisolone; CHOP: cyclophosphamide, doxorubicin, vincristine and prednisolone; CyA: cyclosporine A; Hb: hemoglobin; HV: hyaline vascular type; IgG: immunoglobulin G; IL-6: interleukin-6; IVIG: intravenous immunoglobulin; MOF: multiple organ failure; mPSL: methylprednisolone; PC: plasma cell type; PLT: platelet; PSL: prednisolone; RTX: rituximab; TCZ: tocilizumab; VEGF: vascular endothelial cell growth factor; Ref: reference number.

There are no reports of TAFRO syndrome outside of Japan. However, we found one report of multicentric Castleman's disease in a 4-year-old Hispanic girl with thrombocytopenia, anasarca and renal failure \[[@B17]\]. Although the authors diagnosed the patient with multicentric Castleman's disease and did not comment on reticulin fibrosis of the bone marrow, her clinical characteristics were quite similar to those of our patient and to other cases of TAFRO syndrome. The question remains whether TAFRO syndrome should be classified as a distinct disease entity rather than as an atypical subtype of multicentric Castleman's disease. All of the features of TAFRO syndrome can be seen in severe flares of multicentric Castleman's disease. For example, anasarca and organomegaly are common \[[@B11]\], and thrombocytopenia and renal dysfunction are frequently reported in Castleman's disease \[[@B10],[@B14]-[@B17]\]. In contrast, reticulin fibrosis of the bone marrow occurs less frequently, but it is not specific for TAFRO syndrome or for multicentric Castleman's disease. Establishing TAFRO syndrome as an independent disease entity remains controversial. Further investigation with clinical and pathological studies is necessary to establish TAFRO syndrome as a new syndromic disease.

Conclusions
===========

It is important to note that TAFRO syndrome occurs not only in adults, but also in adolescents. In the acute phase, TAFRO syndrome should be treated with rapid and strong immunosuppressive therapy including TCZ to prevent a fatal outcome. We believe that cytokine profiling is useful not only to assess the pathogenesis but also to monitor disease activity of this rare disease.
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